Biotechnology company developing cancer molecule therapeutics.
Ambagon Therapeutics has raised €75M across 1 funding round from 8 investors, most recently a Series A round in Jan 2022. Based in Eindhoven, Netherlands; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2022-01-07 | Series A | €75M |
| AbbVie Ventures,Droia Ventures,Inkef Capital,Mission BioCapital,MRL Ventures Fund,Nextech Invest+2 more |
| View deal → |
